title: High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
abstract: We evaluated the differential effect of platelet count in platelet-rich plasma (PRP) on the level of ex vivo inhibition of platelet aggregation provided by abciximab, eptifibatide, and tirofiban as part of a randomized, comparative trial of these agents on platelet function in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Platelet count <350 K/microL in PRP reduced measured platelet inhibition by abciximab, but not eptifibatide nor tirofiban. This observation suggests the need for standardized, uniform platelet counts in PRP during future comparisons of the degree of platelet inhibition by these agents.
authors.affiliation: The Carl and Edyth Lindner Center for Clinical Cardiovascular Research, Cincinnati, Ohio 45219, USA. lindner@healthall.com.
authors.forename: D J
authors.initials: DJ
authors.lastname: Kereiakes
authors.forename: T M
authors.initials: TM
authors.lastname: Broderick
authors.forename: E M
authors.initials: EM
authors.lastname: Roth
authors.forename: D
authors.initials: D
authors.lastname: Whang
authors.forename: M
authors.initials: M
authors.lastname: Mueller
authors.forename: P
authors.initials: P
authors.lastname: Lacock
authors.forename: L C
authors.initials: LC
authors.lastname: Anderson
authors.forename: W
authors.initials: W
authors.lastname: Howard
authors.forename: C
authors.initials: C
authors.lastname: Blanck
authors.forename: J
authors.initials: J
authors.lastname: Schneider
authors.forename: C A
authors.initials: CA
authors.lastname: Abbottsmith
mesh_terms: D000077284:Abciximab; D000789:Angina, Unstable / Q000097:blood* / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D015986:Confounding Factors, Epidemiologic; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology*; D008297:Male; D010455:Peptides / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010976:Platelet Count; D010979:Platelet Function Tests; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab